1
|
Size-based enrichment of exfoliated tumor cells in urine increases the sensitivity for DNA-based detection of bladder cancer. PLoS One 2014; 9:e94023. [PMID: 24732047 PMCID: PMC3986060 DOI: 10.1371/journal.pone.0094023] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2013] [Accepted: 03/12/2014] [Indexed: 01/23/2023] Open
Abstract
Bladder cancer is diagnosed by cystoscopy, a costly and invasive procedure that is associated with patient discomfort. Analysis of tumor-specific markers in DNA from sediments of voided urine has the potential for non-invasive detection of bladder cancer; however, the sensitivity is limited by low fractions and small numbers of tumor cells exfoliated into the urine from low-grade tumors. The purpose of this study was to improve the sensitivity for non-invasive detection of bladder cancer by size-based capture and enrichment of tumor cells in urine. In a split-sample set-up, urine from a consecutive series of patients with primary or recurrent bladder tumors (N = 189) was processed by microfiltration using a membrane filter with a defined pore-size, and sedimentation by centrifugation, respectively. DNA from the samples was analyzed for seven bladder tumor-associated methylation markers using MethyLight and pyrosequencing assays. The fraction of tumor-derived DNA was higher in the filter samples than in the corresponding sediments for all markers (p<0.000001). Across all tumor stages, the number of cases positive for one or more markers was 87% in filter samples compared to 80% in the corresponding sediments. The largest increase in sensitivity was achieved in low-grade Ta tumors, with 82 out of 98 cases positive in the filter samples (84%) versus 74 out of 98 in the sediments (75%). Our results show that pre-analytic processing of voided urine by size-based filtration can increase the sensitivity for DNA-based detection of bladder cancer.
Collapse
|
2
|
Miyake M, Sugano K, Sugino H, Imai K, Matsumoto E, Maeda K, Fukuzono S, Ichikawa H, Kawashima K, Hirabayashi K, Kodama T, Fujimoto H, Kakizoe T, Kanai Y, Fujimoto K, Hirao Y. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. Cancer Sci 2010; 101:250-8. [PMID: 19843069 PMCID: PMC11159328 DOI: 10.1111/j.1349-7006.2009.01334.x] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
The fibroblast growth factor receptor (FGFR)-3 gene encodes a receptor tyrosine kinase that is frequently mutated in non-muscle invasive bladder cancer (NMIBC). A sensitive and quantitative assay using peptide nucleic acid-mediated real-time PCR was developed for detecting FGFR3 mutations in the urine samples and evaluated as a molecular marker for detecting intravesical recurrence of NMIBC in patients undergoing transurethral resection of bladder tumor. FGFR3 mutation was examined in tumor tissues and serially taken pre- and postoperative urine sediments in 45 NMIBC patients with a median follow up of 32 months. FGFR3 mutations were detected in 53.3% (24/45) of primary tumor tissues, among which intravesical recurrence developed in 37.5% (9/24) of cases. FGFR3 mutation in the primary tumor was not a significant prognostic indicator for recurrence, while the proportion of FGFR3 mutation (i.e. tumor cellularity was >or=11%) in the preoperative urine sediments was a significant indicator for recurrence in patients with FGFR3 mutations in the primary tumors. FGFR3 mutations were detected in 78% (7/9) of postoperative urine samples from recurrent cases with FGFR3 mutations in the tumor, while no mutations were detected in the urine of 15 non-recurrent cases. Urine cytology was negative in all cases with FGFR3 mutations in the primary tumors, while the sensitivity of cytological examination was as high as 56% (5/9) in cases showing wild-type FGFR3 in the primary tumors. Urine FGFR3 mutation assay and cytological examination may be available in the future as complementary diagnostic modalities in postoperative management of NMIBC.
Collapse
Affiliation(s)
- Makito Miyake
- Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, 4-9-13 Yonan, Utsunomiya, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Sugano K, Kakizoe T. Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging. ACTA ACUST UNITED AC 2007; 3:642-52. [PMID: 17149381 DOI: 10.1038/ncpuro0649] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2006] [Accepted: 09/26/2006] [Indexed: 11/09/2022]
Abstract
Molecular biology is expected to provide new tools and approaches to assess the prognosis of patients with bladder cancer, by providing information on the risks of tumor recurrence and progression from superficial bladder cancer to an invasive phenotype. Genetic and epigenetic alterations have been closely associated with bladder carcinogenesis and progression, although most of these are still under investigation in a preclinical setting. This article highlights current findings from molecular studies, and describes their potential application in molecular staging of bladder cancer.
Collapse
Affiliation(s)
- Kokichi Sugano
- Oncogene Research Unit/Cancer Prevention Unit in Tochigi Cancer Center Research Institute, Utsunomiya, Japan
| | | |
Collapse
|
4
|
Chihara Y, Sugano K, Kobayashi A, Kanai Y, Yamamoto H, Nakazono M, Fujimoto H, Kakizoe T, Fujimoto K, Hirohashi S, Hirao Y. Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene. J Transl Med 2005; 85:895-907. [PMID: 15880137 DOI: 10.1038/labinvest.3700268] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Loss of ABO blood group antigen expression has been reported in transitional cell carcinoma (TCC) of the bladder. Synthesis of the ABO blood group antigen was genetically determined by allelic variants of the ABO gene assigned on 9q34.1. We analyzed loss of heterozygosity (LOH) and promoter hypermethylation of the ABO gene in TCC and compared them with alterations of A antigen expression in TCC, dysplasia and normal urothelium. A total of 81 samples of TCC of the bladder obtained from transurethral resection (TUR) (n=44) and radical cystectomy (n=37) were examined. Expression of the A antigen was evaluated by immunohistochemical staining (IHC) using anti-A antigen monoclonal antibody. LOH of the ABO gene locus was examined by blunt-end single-strand DNA conformational polymorphism (SSCP) analysis using flouresence-based auto sequencer. Promoter hypermethylation of the ABO gene were examined by bisulfite PCR-SSCP (BiPS) analysis and/or methylation-specific PCR (MSP). Loss of A allele and/or hypermethylation were significantly associated with abnormal expression of the A antigen in cases undergoing TUR (P=0.02) and radical cystectomy (P=0.0005). For the analysis of the concomitant dysplasia in 23 cases with TCC of the bladder, the expression of the A antigen was maintained, regardless of the A allelic loss or methylation status in the tumor. In conclusion, A allelic loss and hypermethylation in the promoter region of the ABO gene showed significant correlation with reduction of A antigen expression in TCC, while the expression of the A antigen is maintained in concomitant dysplasia or normal urothelium, suggesting that loss of the ABO gene and/or its promoter hypermethylation is a specific marker for TCC.
Collapse
Affiliation(s)
- Yoshitomo Chihara
- Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Tochigi 320-0834, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Ozawa S, Sugano K, Sonehara T, Fukuzono S, Ichikawa A, Fukayama N, Taylor M, Miyahara Y, Irie T. High Resolution for Single-Strand Conformation Polymorphism Analysis by Capillary Electrophoresis. Anal Chem 2004; 76:6122-9. [PMID: 15481962 DOI: 10.1021/ac049385k] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Since the successful completion of the Human Genome Project, increasing concern is being directed toward the polymorphic aspect of the genome and its clinical relevance. A form of single-strand DNA-conformation polymorphism analysis (SSCP) employing nondenaturing slab-gel electrophoresis (SGE) is applicable to the genetic diagnosis of bladder cancer from urine samples. To bring this technique into routine clinical practice, the use of capillary electrophoresis (CE) is naturally favorable in terms of speed and automation. However, the resolving power of SSCP, a prerequisite basis for reliability required in diagnostics, remains as a challenge for CE systems. We thus focused on this topic and conducted studies on CE instruments equipped with a single capillary or an array of multiple capillaries, using the resolution (Rs) as a quantitative scale for the resolving power. Polymer concentration and buffer are shown to be the decisive parameters. High Rs values of >2.5 are achieved for representative SNPs markers under the optimized conditions, without sacrificing such intrinsic advantages of CE over SGE as the 10-fold quicker migration time and operation that is reproducible, continuous, and automatic. The strategies presented broaden the limits of CE in both the current and related applications.
Collapse
Affiliation(s)
- Satoshi Ozawa
- Central Research Laboratory, Hitachi, Ltd., Kokubunji, Tokyo 185-8601, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Horikawa Y, Sugano K, Shigyo M, Yamamoto H, Nakazono M, Fujimoto H, Kanai Y, Hirohashi S, Kakizoe T, Habuchi T, Kato T. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ. J Urol 2003; 169:1541-5. [PMID: 12629411 DOI: 10.1097/01.ju.0000046242.55722.1c] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
PURPOSE We elucidated the role of methylation in the promoter region of the 1 gene in bladder carcinogenesis, particularly in those comprising carcinoma in situ. MATERIALS AND METHODS A total of 49 cases of transitional cell carcinoma of the bladder obtained from transurethral resection were examined. Methylation status of the 1 promoter region was analyzed by methylation specific polymerase chain reaction from chemically modified DNA after Na-bisulfite treatment. Loss of heterozygosity on 16q was examined by blunt end single strand DNA conformation polymorphism using 4 tetranucleotide repeat microsatellite markers assigned on 16q13 to 22.1. E-cadherin expression was evaluated by immunostaining on formalin fixed, paraffin embedded tissue sections using anti E-cadherin murine monoclonal antibody, HECD1 and standard avidin-biotin immunoperoxidase complex technique. RESULTS Analysis of the 49 bladder transitional cell carcinoma samples showed 1 promoter methylation in 23 (47%). Methylation of the 1 gene did not correlate with tumor stage (p = 0.2097) but with high grade transitional cell carcinoma (p = 0.0416). 1 promoter methylation was observed at a significantly higher frequency in the carcinoma in situ positive group than in the carcinoma in situ negative group (16 of 18 cases or 89% versus 7 of 31 or 23%, p <0.0001) and it strongly correlated with abnormal E-cadherin expression (p <0.0001). We found 16q loss of heterozygosity in 16 of 47 cases (34%), which correlated with higher histological grade (p = 0.0069) but not with the presence of the carcinoma in situ component (p = 0.1235). CONCLUSIONS This study showed that 1 gene promoter methylation is strongly associated with bladder transitional cell carcinoma comprising carcinoma in situ.
Collapse
Affiliation(s)
- Yohei Horikawa
- Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute and Department of Urology, Tochigi Cancer Hospital, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Miyakura Y, Sugano K, Konishi F, Fukayama N, Igarashi S, Kotake K, Matsui T, Koyama Y, Maekawa M, Nagai H. Methylation profile of the MLH1 promoter region and their relationship to colorectal carcinogenesis. Genes Chromosomes Cancer 2003; 36:17-25. [PMID: 12461746 DOI: 10.1002/gcc.10134] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Methylation of the MLH1 promoter region has been suggested to be a principal mechanism of gene inactivation in sporadic microsatellite instability (MSI)-positive colorectal carcinoma. Recently, we have shown a novel methylation profile of the MLH1 promoter region (i.e., full, partial, and no methylation), among which full methylation was strongly associated with MSI. In this study, to confirm whether methylation requires the involvement of both alleles, we studied the MLH1 promoter region concerning the methylation profile and allelic loss. Furthermore, we studied correlations of methylation profiles with genetic alternations such as loss of heterozygosity (LOH) of the TP53 locus and KRAS mutation. Eighty-eight tumors were classified as full (n = 14), partial (n = 26), and no methylation (n = 48). Full methylation was observed in 78% (14/18) of high-frequency MSI, in which all CpG sites in the promoter region were methylated. Full methylation differed significantly from partial methylation regarding absence of TP53 LOH (0/12) and KRAS mutation (0/14). In cases with full methylation, we could show biallelic methylation by use of a single-base nucleotide polymorphism in the promoter. However, this did not accompany LOH of the MLH1 locus. In contrast, there were no significant differences in molecular features between partial and no methylation, except for low frequencies of LOH of the MLH1 locus (P = 0.02). In conclusion, biallelic extensive methylation of the MLH1 promoter region plays a significant role in gene inactivation and is independent of KRAS mutation and TP53 LOH.
Collapse
|
8
|
Sandberg AA. Cytogenetics and molecular genetics of bladder cancer: a personal view. AMERICAN JOURNAL OF MEDICAL GENETICS 2002; 115:173-82. [PMID: 12407698 DOI: 10.1002/ajmg.10693] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The cytogenetic and molecular genetic aspects that may be involved in the pathogenesis of bladder cancer are presented. Although anomalies of chromosome 9 may play an initial causative role in this cancer, the subsequent events, involving a succession of genetic changes, are less established or understood. This presentation is a distillation of what generally are considered to be the cytogenetic and molecular genetic events that constitute the array of changes underlying bladder cancer.
Collapse
Affiliation(s)
- Avery A Sandberg
- Department of DNA Diagnostics at St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, USA.
| |
Collapse
|
9
|
SHIGYO MASANORI, SUGANO KOKICHI, TOBISU KENICH, TSUKAMOTO TAIJI, SEKIYA TAKAO, KAKIZOE TADAO. MOLECULAR FOLLOWUP OF NEWLY DIAGNOSED BLADDER CANCER USING URINE SAMPLES. J Urol 2001. [DOI: 10.1016/s0022-5347(05)65753-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- MASANORI SHIGYO
- From the Division of Clinical Laboratory, Department of Urology, National Cancer Center Hospital and Oncogene Division, National Cancer Center Research Institute, Tokyo, Department of Urology, Sapporo Medical University, Hokkaido, Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Tochigi, Japan
| | - KOKICHI SUGANO
- From the Division of Clinical Laboratory, Department of Urology, National Cancer Center Hospital and Oncogene Division, National Cancer Center Research Institute, Tokyo, Department of Urology, Sapporo Medical University, Hokkaido, Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Tochigi, Japan
| | - KEN-ICH TOBISU
- From the Division of Clinical Laboratory, Department of Urology, National Cancer Center Hospital and Oncogene Division, National Cancer Center Research Institute, Tokyo, Department of Urology, Sapporo Medical University, Hokkaido, Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Tochigi, Japan
| | - TAIJI TSUKAMOTO
- From the Division of Clinical Laboratory, Department of Urology, National Cancer Center Hospital and Oncogene Division, National Cancer Center Research Institute, Tokyo, Department of Urology, Sapporo Medical University, Hokkaido, Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Tochigi, Japan
| | - TAKAO SEKIYA
- From the Division of Clinical Laboratory, Department of Urology, National Cancer Center Hospital and Oncogene Division, National Cancer Center Research Institute, Tokyo, Department of Urology, Sapporo Medical University, Hokkaido, Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Tochigi, Japan
| | - TADAO KAKIZOE
- From the Division of Clinical Laboratory, Department of Urology, National Cancer Center Hospital and Oncogene Division, National Cancer Center Research Institute, Tokyo, Department of Urology, Sapporo Medical University, Hokkaido, Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Tochigi, Japan
| |
Collapse
|
10
|
MOLECULAR FOLLOWUP OF NEWLY DIAGNOSED BLADDER CANCER USING URINE SAMPLES. J Urol 2001. [DOI: 10.1097/00005392-200110000-00014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Fedriga R, Gunelli R, Nanni O, Bacci F, Amadori D, Calistri D. Telomerase activity detected by quantitative assay in bladder carcinoma and exfoliated cells in urine. Neoplasia 2001; 3:446-50. [PMID: 11687956 PMCID: PMC1506205 DOI: 10.1038/sj.neo.7900191] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2001] [Accepted: 07/19/2001] [Indexed: 11/09/2022] Open
Abstract
Early diagnosis is one of the most determining factors for patient survival. The detection of telomerase activity is a potentially promising tool in the diagnosis of bladder and other types of cancer due to the high expression of this enzyme in tumor cells. We carried out a quantitative evaluation of telomerase activity in urine samples in an attempt to determine a cut-off capable of identifying cancer patients. Telomerase activity was quantified by fluorescence TRAP assay in urine from 50 healthy volunteers and in urine and bioptic tumor samples from 56 previously untreated bladder cancer patients and expressed in arbitrary enzymatic units (AEU). Telomerase activity in urine ranged from 0 to 106 AEU (median 0) in healthy donors and from 0 to 282 AEU (median 87) in patients with cancer. A telomerase expression higher than the cut off value determined by receiver operating characteristic (ROC) analysis was observed in 78% of cases, regardless of tumor grade and in 71% (15/21) of cases of nonassessable or negative cytology. The quantitative analysis of telomerase activity in urine enabled us to define cut-off values characterized by different sensitivity and specificity. Cytologic and telomerase determination, used sequentially, enabled us to detect about 90% of tumors.
Collapse
Affiliation(s)
- Roberta Fedriga
- Istituto Oncologico Romagnolo, Pierantoni Hospital, Forlì, Italy
| | | | - Oriana Nanni
- Istituto Oncologico Romagnolo, Pierantoni Hospital, Forlì, Italy
| | | | - Dino Amadori
- Department of Medical Oncology, Pierantoni Hospital, Forlì, Italy
| | - Daniele Calistri
- Istituto Oncologico Romagnolo, Pierantoni Hospital, Forlì, Italy
| |
Collapse
|
12
|
Böckmann B, Grill HJ, Giesing M. Molecular characterization of minimal residual cancer cells in patients with solid tumors. BIOMOLECULAR ENGINEERING 2001; 17:95-111. [PMID: 11222984 DOI: 10.1016/s1389-0344(00)00073-3] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The failure to reduce the mortality of patients with solid tumors is mainly a result of the early dissemination of cancer cells to secondary sites, which is usually missed by conventional diagnostic procedures used for tumor staging. PCR was shown to be superior to conventional techniques in detecting circulating tumor cells and micrometastases allowing the identification of one tumor cell in up to 10(7) normal cells in various sources such as blood, bone marrow, lymph nodes, urine or stool. The methods used are based on the detection of either genomic alterations in oncogenes and tumor suppressor genes or on the mRNA expression of tissue-specific and tumor-associated genes. The additional implementation of techniques for cancer cell purification had a significant impact on analytical sensitivity and specificity of MRCC detection. For patients with e.g. melanoma, breast, colorectal or prostate cancer it was demonstrated that the presence of disseminated cancer cells defines a subgroup of patients with reduced time to recurrence. The possibility to use easily accessible body fluids as a source for MRCC detection enables longitudinal observations of the disease. In this review we discuss the potential of molecular characterization of MRCC as a tool to improve prognostication, therapy selection and drug targeting as well as therapy monitoring.
Collapse
Affiliation(s)
- B Böckmann
- Institute for Molecular NanoTechnology, Berghäuser Strasse 295, 45659, Recklinghausen, Germany
| | | | | |
Collapse
|
13
|
DETECTION OF LOSS OF HETEROZYGOSITY IN THE P53 TUMOR-SUPPRESSOR GENE WITH PCR IN THE URINE OF PATIENTS WITH BLADDER CANCER. J Urol 2000. [DOI: 10.1097/00005392-200003000-00093] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
14
|
FRIEDRICH MARTING, ERBERSDOBLER ANDREAS, SCHWAIBOLD HARTWIG, CONRAD STEFAN, HULAND EDITH, HULAND HARTWIG. DETECTION OF LOSS OF HETEROZYGOSITY IN THE P53 TUMOR-SUPPRESSOR GENE WITH PCR IN THE URINE OF PATIENTS WITH BLADDER CANCER. J Urol 2000. [DOI: 10.1016/s0022-5347(05)67878-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- MARTIN G. FRIEDRICH
- From the Department of Urology and Institute for Pathology, University Hospital Eppendorf, University of Hamburg, Germany
| | - ANDREAS ERBERSDOBLER
- From the Department of Urology and Institute for Pathology, University Hospital Eppendorf, University of Hamburg, Germany
| | - HARTWIG SCHWAIBOLD
- From the Department of Urology and Institute for Pathology, University Hospital Eppendorf, University of Hamburg, Germany
| | - STEFAN CONRAD
- From the Department of Urology and Institute for Pathology, University Hospital Eppendorf, University of Hamburg, Germany
| | - EDITH HULAND
- From the Department of Urology and Institute for Pathology, University Hospital Eppendorf, University of Hamburg, Germany
| | - HARTWIG HULAND
- From the Department of Urology and Institute for Pathology, University Hospital Eppendorf, University of Hamburg, Germany
| |
Collapse
|
15
|
Olumi AF. A critical analysis of the use of p53 as a marker for management of bladder cancer. Urol Clin North Am 2000; 27:75-82, ix. [PMID: 10696247 DOI: 10.1016/s0094-0143(05)70236-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Delineating the important molecular pathways in carcinogenesis has helped develop and advance the field of molecular diagnosis. Bladder cancer has served as an excellent model in translating some of the advances from the laboratory to clinical settings. Many investigators have examined the use of p53 to help manage patients with bladder cancer who are at high risk of tumor progression. This article reviews the clinical studies that have used p53 as a marker in bladder carcinoma and concludes by determining whether routine assessment of the p53 tumor suppressor gene/protein is indicated at this time.
Collapse
Affiliation(s)
- A F Olumi
- Division of Urologic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
| |
Collapse
|
16
|
Sugano K, Taniguchi T, Saeki M, Tsunematsu Y, Tomaru U, Shimoda T. Germline p53 mutation in a case of Li-Fraumeni syndrome presenting gastric cancer. Jpn J Clin Oncol 1999; 29:513-6. [PMID: 10645809 DOI: 10.1093/jjco/29.10.513] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- K Sugano
- Division of Gene Testing and DNA Analysis, Tochigi Cancer Center, Utsunomiya, Japan.
| | | | | | | | | | | |
Collapse
|
17
|
Shigyo M, Sugano K, Fukayama N, Taniguchi T, Tobisu K, Fujimoto H, Doi N, Niwakawa M, Shimamura K, Tsukamoto T, Sekiya T, Kakizoe T. Allelic loss on chromosome 9 in bladder cancer tissues and urine samples detected by blunt-end single-strand DNA conformation polymorphism. Int J Cancer 1998; 78:425-9. [PMID: 9797129 DOI: 10.1002/(sici)1097-0215(19981109)78:4<425::aid-ijc6>3.0.co;2-w] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Allelic loss on chromosome 9 is the most frequent and earliest genetic event in bladder carcinogenesis, and its detection in urine samples would be useful for detecting bladder cancer. A highly sensitive method to detect loss of heterozygosity (LOH) at 5 polymorphic loci on chromosome 9p and 9q was developed by the use of blunt-end single-strand DNA conformation polymorphism (blunt-end SSCP) analysis. Tumor tissues, urine samples and peripheral blood lymphocytes from 34 patients with transitional cell carcinoma of the bladder were analyzed. LOHs on 9p and/or 9q were found in 24 (71%) of 34 tumor samples and 23 (70%) of 33 urine samples, while no allelic loss was detected in 20 urine samples from benign urothelial diseases. The frequency of allelic loss in tumor tissues was 67%, 71% and 80% in the pTa, pT1 and > or = pT2 stages and 50%, 80% and 79% in G1, G2 and G3 tumors, respectively. In comparison with a urine cytological examination, LOH on chromosome 9 was detected in 70% of urine samples diagnosed as transitional cell carcinoma, 67% of those as atypia and 70% of those as no malignant cells. Thus, detection of LOH on chromosome 9 from urine samples by blunt-end SSCP is a more sensitive diagnostic modality than cytologic examination for detecting bladder cancer. It would be useful for postoperative management of bladder cancer, particularly when the allelic loss is revealed in the tumor tissues obtained at first surgery.
Collapse
Affiliation(s)
- M Shigyo
- Division of Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|